Trial Profile
Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Borderline personality disorders
- Focus Therapeutic Use
- Acronyms BTX-BPD
- 01 Feb 2022 Primary endpoint Zanarini Scale for Borderline personality disorder (ZAN-BPD) has been met, as per Results published in the Journal of Psychopharmacology
- 01 Feb 2022 Results published in the Journal of Psychopharmacology
- 28 May 2020 Status changed from recruiting to completed.